Publicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (25)

2022

  1. Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

    Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48

  2. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  3. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354

2021

  1. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative

    Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811

  2. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

    Journal of Thoracic Oncology, Vol. 16, Núm. 4, pp. 686-696

  3. The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

    Leukemia and Lymphoma

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 10, pp. 1599-1610

  2. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 499-519

  3. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 15, Núm. 9, pp. 1409-1424

2019

  1. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 377-407

  2. Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis

    Cancer Treatment Reviews, Vol. 77, pp. 11-19

  3. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  4. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]

    European Urology

  2. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

2017

  1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 9, pp. 1274-1284

  2. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

    Lung Cancer, Vol. 112, pp. 181-187

  3. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

  4. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 34, pp. 3867-3876